For the Culture By The Culture. ISSN: 3064-9331.
Legal cannabis has generated nearly $25 billion in tax revenue, with $4.4 billion collected in 2024 alone. States benefit significantly, funding various community programs. However, equity issues remain, as many who contributed to legalization are still marginalized. The promise of justice is overshadowed by bureaucracy and economic barriers for legacy growers.
Congressman Dave Joyce wants credit for fixing weed. But his new legislation might just carve up the movement and hand it to corporate stakeholders. Behind the clean language is a blueprint for state-by-state chaos, not freedom. If this is legalization, it’s legalization without justice—and the people who built the culture are still waiting outside the gates.
The DEA is dragging its feet on cannabis rescheduling despite over 43,000 public comments and a formal Schedule III recommendation from HHS. What’s the hold-up? This deep-dive exposes the legal limbo, political stall tactics, and why America’s weed policy is still frozen in time.
The Ann Arbor Hash Bash, held annually since 1972, symbolizes the ongoing fight for cannabis rights and culture. Headlined by Tommy Chong in 2025, it embodies protest and celebration against restrictive drug laws. The event attracts diverse generations, emphasizing the fight for freedom and autonomy amid the commercialization of cannabis culture.
In a bizarre twist of bureaucratic brilliance, the DEA has reclassified marijuana as a leafy green vegetable—officially adding it to the American food pyramid. From salad bowls to school lunches, the War on Drugs just got edible. Satirical? Yes. Unbelievable? Barely.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
